Table 2 Clinical data stratified by clinical trial.
Total (n = 24) | KarMMa-3 (n = 17) | KarMMa-2 (n = 7) | p-value | ||
|---|---|---|---|---|---|
Age (years, mean, SD) | 61.0 (9.87) | 61.1 (9.63) | 61.0 (11.0) | 0.9825 | |
Sex (m / f, n, %) | 18 (75%) / 6 (25%) | 13 (76%) / 4 (24%) | 5 (71%) / 2 (29%) | 0.7954 | |
Ethnicity (white, black or African American, n, %) | 21 (87.5%) / 3 (12.5%) | 15 (88%) / 2 (12%) | 6 (86%) / 1 (14%) | 0.8652 | |
Best Overall Response | Stringent complete response | 12 (50%) | 8 (47.1%) | 4 (57.1%) | 0.2825 |
Complete response | 2 (8.8%) | 1 (5.9%) | 1 (14.3%) | ||
Very good partial response | 4 (16.7%) | 4 (23.5%) | 0 (0%) | ||
Partial response | 2 (8.3%) | 1 (5.9%) | 1 (14.3%) | ||
Minimal response | 1 (4.2%) | 0 (0%) | 1 (14.3%) | ||
Stable disease | 3 (12.5%) | 3 (17.6%) | 0 (0%) | ||
Progression Free Survival (months, mean, SD) | 18.9 (10.4) | 19.2 (11.5) | 18.4 (8.3) | 0.8696 | |
